Lysoway Therapeutics

Lysoway Therapeutics is pioneering the field of lysosomal ion-channel biology and next-generation drug discovery. Using our proprietary screening platforms and structure-guided design technologies, we develop highly brain-penetrant, selective, and potent small-molecule modulators targeting key lysosomal ion channels such as TRPML1 and TMEM175. These ion channels are essential regulators of intracellular signaling and play a central role in maintaining lysosomal health and autophagic flux—critical processes that often break down in age-related neurodegenerative diseases and lysosomal storage disorders. By precisely restoring lysosomal function and rebalancing autophagy, Lysoway’s therapeutics aim to correct the core cellular defects that drive these conditions and unlock new possibilities for meaningful patient impact.